Breakthrough treatments to increase the healthspan and lifespan of humans.
We are a group of world-renowned specialists.
About us
Our passion is to help the world re-imagine what it means to age.
Our biology suggests that we are capable of living over 120 years, yet the average U.S. citizen doesn’t make it past their 70’s. Less than 5% make it to their nineties, a mere 1% become centenarians, and only one single person in recorded history has ever made it to 120 years old – in other words, we’re leaving a lot on the table.
REGENERATIVE MEDICINE
is leading the way in the medical revolution and will continue to evolve until illness based treatments are replaced by wellness based solutions.
Eterna Health beliefs
@jase_stevens Internationally Published Fitness Model Body Composition Expert @manthefup_ Founder
Our mission
Accelerating the world’s transition to the next generation of regenerative medicine by combining cell therapy, gene editing and tissue engineering.
@jordydi, Bikini Athlete, CEO/Owner: @btyl.co @fitwithjordydix
Our vision
Eterna Health’s vision is based on the idea that invasive surgery and pharmaceuticals can be partially replaced by cell biology and gene therapy. Science already uses autologous cells as a therapeutic and corrective agent and biology is ready to take the ‘first slices’ of the market away from chemistry. Eterna’s unique partnerships with Minicircle and Viswanathan labs helps with a competitive advantage as a leader in the market of mesenchymal stromal cell therapies and gene therapy.
Meet Dr. Adeel Khan, M.D.
Adeel Khan, M.D., is a Canadian Board Certified Physician who is the founder of Eterna Health Clinics. He brings global recognition from other health care professionals, elite athletes, and patients from all walks of life. Dr. Khan is recognized as one of the pioneers in the field of interventional orthobiologics and is highly respected for his contributions for clinical translation.
Fueled by a passion for a deep understanding of the cellular physiology and its repair combined with his dedication to academic research, Dr. Khan has partnered with scientists from around the world in Canada, USA, Mexico, Dubai, Italy, and Japan. The unique clinical experience from working around the world and accumulated scientific knowledge, we have designed Eterna clinics to be the most unique offering in the world. In addition, Dr. Khan’s participation in multiple international associations has resulted in a global reputation as a respected regenerative medicine physician scientist.
Dr. Adeel Khan completed his MD from the University of Ottawa in Canada.
After training in sports medicine & interventional pain, he specialized in regenerative medicine. Driven by his passion to improve health, he co-founded Xalt and is the Chief Scientific Officer of Science & Humans. He is also the chief medical officer for Minicircle, the world’s first reversible gene therapy. He has a special interest in using interventional procedures to treat weightlifting injuries, chronic neck and back pain. Dr. Khan also teaches medical students and residents, and is an Assistant Clinical Professor at University of Toronto.
Dr. Khan's memberships
- Spine Intervention Society (SIS)
- The International Society for Stem Cell Research (ISSCR)
- International Cartilage Restoration Society (ICRS)
- International Society for Extracellular Vesicles (ISEV)
- Tissue Engineering and Regenerative Medicine International Society (TERMIS)
Dr. Khan's contributions to regenerative medicine
- Key opinion leader for The American College of Regenerative Medicine, the authority in North America for advocacy and best practices
- Recruited to treat Mohammed Alabbar with orthobiologics, founder of EMAAR (owner of the tallest buildings in the world including Bhurj-khalifa)
- Treating the most elite Olympic, NFL, NHL, NBA, and MLB athletes with mesenchymal stem cells, exosomes and platelet-rich plasma injections
- Pioneering regenerative medicine research including currently as a co-investigator for a Health Canada approved clinical trial for mesenchymal stem cells: click here
- Developing proprietary platelet-rich plasma derived exosomes
- Presenting at national and international regenerative medicine conferences including The Orthobiologics Institute (TOBI) where he collaborated with the pioneer of mesenchymal stem cells: Dr. Arnold Caplan
- First Canadian Doctor to publish and perform Intraosseous Platelet-Rich Plasma injections for advanced osteoarthritis: click here
- Pioneering interventional allogenic stem cell spine cell treatments including treating Royal Family members throughout United Arab Emirates
- Doctor to many of the highest profile celebrities, athletes, and influential people around the world
There are several approaches to regenerative medicine, including stem cell therapy, regenerative pharmacology and gene therapy.
Meet Dr. David R. Smith
Dr. Smith’s academic interests have always been complex. In his earliest years he was fascinated with understanding human behavior from a mind body perspective.
He graduated summa cum laude from the University of Pennsylvania, with a combined degree in Biology, Psychology, and Physical Anthropology. Upon graduation, he was accepted into Phi Beta Kappa, the most prestigious academic honors society for university graduates.
Dr. Smith received his medical degree from the Columbia College of Physicians and Surgeons in New York City, completed an internship in Internal Medicine and a residency in Anesthesiology at the Cleveland Clinic Foundation.
Dr. Smith is an expert in interventional regenerative and cellular medicine.
Given his interests in human behavior and biological systems, Dr. Smith soon specialized in helping those with pain. He sought training in Seattle, where he completed an Astra Fellowship in Regional Anesthesia where he fine-tuned his use of nerve blocks to bring safety, comfort, and relief of pain to his patients.
Dr. Smith is an expert in the use of ultrasound imaging and injections for the diagnosis and treatment of joint, ligament, and tendon pathology. He has safely performed over 10,000 image-guided procedures and now uses delivery techniques gleaned over decades to precisely place regenerative cells for optimal growth and repair.
He serves on the faculty at several national conferences, and he is followed on LinkedIn by over 2000 medical professionals. He is board certified by the American Board of Anesthesiology and licensed to practice in Ontario, New York, Colorado, Florida, Texas, and Illinois.
Eterna Health has developed protocols to synergistically combine peptides with MSCs. We can increase the anti-inflammatory, immunomodulatory and regenerative benefits. by combining our MSCs with Thymosin alpha-1, and we are able to get a more potent immunomodulatory effect.
Meet Dr. Michael Gofeld
Dr. Gofeld completed a residency program in Anesthesiology at the University of Tel Aviv in 2001 and fellowship training in Chronic Pain at the University of Toronto in 2005. He defended his Doctorate thesis in Spinal Sonography at the University of Maastricht.
Dr. Gofeld worked in the Sunnybrook Health Sciences Centre until 2008. He developed the first collaborative pain management program in the province of Ontario for palliative care patients. Then, he was recruited by the University of Washington in Seattle and served as the Director of Clinical Operations at the Center for Pain Relief (CPR).
The CPR was the first multidisciplinary pain program in the World that started in 1967 and immensely influenced the development of the entire Chronic Pain discipline. Dr. Gofeld subsequently led the Neuromodulation Program and was cross-appointed with the Department of Neurological Surgery.
Dr. Gofeld is a renowned expert and speaker at international conferences and forums on chronic pain.
He returned to Ontario in 2013 and joined the Department of Anesthesia at the University of Toronto. Dr. Gofeld substantially contributed to developing and launching the Toronto Academic Pain Medicine Institute (TAPMI). He served as an interim Medical Director of the Women’s College Pain Clinic, the Advisor on Chronic Pain at the Department of Anesthesia, and the Chronic Pain Registry Committee vice-chair at the Adult Chronic Pain Network Advisory for the Ministry of Health and Long-Term Care of Ontario. Dr. Gofeld devoted time and effort to developing the Neuromodulation Program at St Michael’s Hospital and Chronic Pain education at the University of Toronto. He was appointed as Associate Professor.
For two years, Dr. Gofeld served as an Assessor for the College of Physicians and Surgeons of Ontario. He served as a member of the editorial boards of several prestigious scientific journals. He founded the Interventional Special Interest Group at the Canadian Pain Society, the first continuing medical education program for practicing pain physicians in Canada.
He started first in North America CME courses in interventional sonography for practicing pain physicians. He is currently holding an appointment as a Director at the World Academy of Pain Medicine United. Although Dr. Gofeld left the academic practice in 2018, he remained connected with the University of Toronto Pain Medicine Royal College residency program mentoring trainees and helping them acquire the necessary skills. He continued practicing in a community setting, focusing on advanced spine methods, regenerative medicine, and spine sports injuries.
Dr. Gofeld has 22 years of clinical experience in spinal, musculoskeletal, and neurological interventions and comprehensive pain management.
Dr. Gofeld authored or co-authored 57 peer-reviewed publications and numerous book chapters. Dr. Gofeld is involved in medical research and development via consulting engagement with industry, startups, and technological incubators. He is an investigator and advisor in Heath Canada and FDA-regulated studies.
Dr. Gofeld is a qualified expert in personal injury and catastrophic assessments C-CAT(P).
Meet Dr. Russell Uppal
Dr. Russell Uppal completed his medical training at the University of Ottawa and completed his residency and fellowship training at the University of Toronto. With a passion for education, he is currently an Assistant Clinical Professor at McMaster University and the University of Toronto. His audiences include medical students and residents both in the classroom and clinical settings and has been nominated for numerous faculty teaching awards.
Dr. Uppal is a member of the Canadian Academy of Sport and Exercise Medicine. His interest in Sports and Regenerative Medicine, is rooted in his personal experiences after regenerative medicine played a key role in his restoring his own health. In addition to his sports medicine practice, Dr. Uppal also divides his clinical time with the emergency department in Toronto. As an Emergency Medicine Physician for over 6 years, he has significant exposure and skills in managing both acute and chronic musculoskeletal injuries and pain. Dr. Uppal also has a special interest and training in ultrasound-guided procedures and orthobiologics. His pursuit of excellence in the field continues, as he is pursuing his Masters in Sports and Exercise Medicine at Western University in association with the Fowler Kennedy Sport Medicine Clinic. His aptitude in the field has allowed him Team Physician opportunities, and he is looking forward to working alongside athletes internationally, in the future.
His passion for sports and regenerative medicine, coupled with his advance critical care experience, makes Dr. Uppal a valuable asset in our approach to providing excellence in patient care.
Eterna Health is accelerating the world's transition to the next generation of regenerative medicine by combining cell therapy, gene editing and tissue engineering.
Meet Dr. Helge Schmitz
Dr. Schmitz grew up in Canada from age 7-12, and went on to graduate from Deutschordengymnasium in Bad Mergentheim, Germany. He served from 1989-1991 in military service in Munich, Germany with the Paramedics and as a career as a Reserve Officer. Helge attended Medical School at the Julius-Maximilians-University in Wuerzburg, Germany from 1991-1998, and then continued to work in the Department of Orthopedic Surgery at the University of Wuerzburg studying under Professor Dr. Med. Jochen Eulert from 1998-2000.
Dr. Schmitz is a specialist on shoulder and knee surgery.
Beginning on 2001, Dr. Schmitz began working in Departments for Orthopedic surgery, and from 2006-2019 worked in Freiburg, Germany as a partner in the Praxisklinik Zaehringen, Athletikum Group as an orthopedic specialist. Over the next decade, Dr. Schmitz worked as the Head of Arthroscopic Surgery at Krankenhaus Salem and performed surgeries in his private practice at the Ethianum Clinic, both located in Heidelberg, Germany.
From 2019 – 2022, Helge had an associated partnership with Dr. med. Michael Lehmann and Professor Dr. med. Felix Zeifang. He proudly became the Head of Shoulder Surgery for the Fontana Clinic in Freiburg, Germany and is now working as a Doctor of the Reuter Clinic in Dubai, UAE. He also frequents the Dubai London Hospital in Dubai, and the Bioscience Clinic Middle East.
Dr. Helge speaks German and English. He is a member of DVSE, AGA, MWE, and BVOU. Helge specializes in arthoscopic shoulder and knee surgery, manual orthopedic medicine/chirotherapy, and extracorporal shock wave therapy.
Meet Dr. Sunny Gandhi
Dr. Gandhi is an innovative practitioner, specializing in performance optimization, career longevity and injury recovery.
As a graduate of D’Youville Chiropractic College, Dr. Gandhi provides unparalleled treatments through his unique combination of soft tissue techniques, such as Active Release (ART), Functional Range Systems (FRS) with Contemporary Medical Acupuncture and joint manipulation to optimize his results. Years of academic and hands-on experience have catapulted his expertise to the front of his field, making him the go-to practitioner for some of the most complicated cases among NCAA, Olympic and professional athletes in the NFL, PSA, and NHL.
Our top FAQs
Stem cells
Stem cells are cells that are necessary for the body to replenish, maintain, and regenerate cells that are lost daily, and have the following two characteristics.
1. Differentiation: Create cells such as blood, nerves, bones, muscles and blood vessels.
2. Self-renewal ability: Produces its own copy cells to replenish and repair defective cells.
If it is earlier, the symptoms will improve immediately after administration, and it is expected that the repair effect will continue for several months. (Effects vary from person to person.)
As we age, the quantity and quality of our stem cells decline. This can lead to a reduction in their ability to differentiate into various cell types and replace damaged or worn-out cells. Additionally, the accumulation of DNA damage over time may make it more difficult for stem cells to divide and maintain proper tissue function.
These changes can contribute to age-related declines in tissue and organ function, which in turn can increase the risk of developing various health problems such as heart disease, stroke, and neurodegenerative diseases. Additionally, the decline in stem cell function can also impact the body’s ability to regenerate and repair damaged tissue, which can further contribute to the aging process.
Exosomes are small, membrane-bound vesicles that are released by cells and contain various biomolecules, such as proteins, nucleic acids, and lipids. They play a role in intercellular communication and can be found in various biological fluids, including blood, urine, and breast milk. Exosomes are also being used for several medical applications, disease diagnosis and regenerative treatments such to reduce inflammation, oxidative stress, increase blood flow, and slow down general degeneration.
Although there are individual differences, we will administer stem cells while observing the health status and observing the patient for 3 months, 6 months, and 12 months after the initial treatment.
Stem cells have the property of accumulating at the damaged site called the “homing phenomenon”. Therefore, it is known that when stem cells are injected into blood, they naturally accumulate at the target site and exert a therapeutic effect.
(Homing phenomenon: A phenomenon in which stem cells transplanted from the periphery reach a niche (lesion site). Induction signals such as cytokines and adhesion factors are secreted from the lesion site, and the stem cells sense the induction signals and accumulate in the lesion site. However, it is known to exert a therapeutic effect.)
- Fat is safer and less burdensome to the body than bone marrow harvest.
- Similar to bone marrow-derived mesenchymal stem cells, adipose-derived stem cells have the ability to differentiate into fat, bone, and cartilage, as well as the ability to differentiate into muscle, which is not found in bone marrow-derived cells.
- It has a strong proliferation ability.
- There is little effect of aging due to proliferation and deterioration of bone differentiation capacity.
Stem cells generally support human growth, and there are more stem cells in childhood than in adults. Stem cells are also present when they mature and stop apparent growth and serve to recruit cells when the tissue is damaged throughout life. Tissue stem cells such as brain and heart are difficult to separate from the body and difficult to use for treatment, so mesenchymal stem cells that can be easily collected from fat etc. are receiving attention.
Mesenchymal stem cells: relatively easy to obtain from adult bone marrow, adipose tissue and dental pulp, and differentiate into not only adipocytes, osteoblasts, adipocytes, muscle cells, chondrocytes but also cells such as internal organs and neurons.
I have the ability. In recent years, it has been reported that mesenchymal stem cells have an immunosuppressive action and have a property of accumulating in tumors, use of mesenchymal stem cells to prevent rejection after transplantation, and cancer gene therapeutic drug Mesenchymal stem cells have also been used in the field of tissue engineering, with research being conducted as carriers.
Stem cells include pluripotent stem cells that can be created from any cells in the body, such as embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells), and tissue stem cells obtained from tissues such as skin and blood It will be. Tissue stem cells that supplement lost cells include bone marrow stem cells and adipose stem cells. Adipose stem cells are characterized by less ethical issues and cancer risk than ES cells and iPS cells, and less invasion of the patient’s body than bone marrow stem cells.
Since we use adipose stem cells cultured from the fat of the patient himself, there is no rejection reaction due to transplantation. It is a highly safe treatment with a low risk of tumor formation found in iPS cells and ES cells. In addition, the wound when collecting fat is about 5 mm and it is a surgery that does not burden the body, and there is no ethical problem like ES cells.
Stemness encompasses the capability of a cell for self-renewal and differentiation. There are several types of stemness, including:
- Totipotency: The ability of a cell to differentiate into any cell type
- Pluripotency: The ability of a cell to differentiate into any of the three germ layers (endoderm, mesoderm, or ectoderm) that give rise to all cells in the body.
- Multipotency: The ability of a cell to differentiate into multiple, but not all, cell types within a particular tissue or organ.
- Unipotency: The ability of a cell to differentiate into only one specific cell type.
exosomes
Vesicles are small, membrane-bound sacs that are found within cells. They can be formed by the cell’s membrane as well as by intracellular organelles, such as the endoplasmic reticulum, Golgi apparatus, and mitochondria. Vesicles play important roles in intracellular transport, storage, and secretion of molecules such as proteins, lipids, and other small molecules. They also play a key role in intercellular communication by facilitating the transfer of molecules between cells, as in the case of exosomes.
Extracellular vesicles (EVs) are a type of vesicle that is released by cells into the extracellular space. They are similar in structure and composition to intracellular vesicles, but they are released into the extracellular environment instead of being retained within the cell.
EVs include various types of vesicles, such as exosomes, microvesicles, and apoptotic bodies, that differ in their size, biogenesis, and cargo. EVs are involved in a variety of physiological and pathological processes, such as intercellular communication, immune response, and cancer progression. They also have potential as diagnostic and therapeutic tools due to their ability to transfer bioactive molecules between cells.
Microvesicles are small, membrane-bound vesicles that are shed from the surface of cells. They are similar in size and composition to exosomes, but they are formed by a different mechanism. Microvesicles are generated by the outward budding and fission of the cell’s plasma membrane, whereas exosomes are formed within the endosomal pathway of the cell.
Microvesicles have been shown to contain various biomolecules, such as proteins, lipids, and nucleic acids, and they have been implicated in a variety of physiological and pathological processes, including intercellular communication, coagulation, and inflammation. Like exosomes, microvesicles also have potential as diagnostic and therapeutic tools due to their ability to transfer bioactive molecules between cells.
Exosomes are small, membrane-bound vesicles that are released by cells and contain various biomolecules, such as proteins, nucleic acids, and lipids. They play a role in intercellular communication and can be found in various biological fluids, including blood, urine, and breast milk. Exosomes are also being used for several medical applications, disease diagnosis and regenerative treatments such to reduce inflammation, oxidative stress, increase blood flow, and slow down general degeneration.
In short, No. Exosomes can vary in their size, composition, and function, depending on the type of cell from which they are released and the physiological or pathological state of the cell. Exosomes can differ in their protein, lipid, and nucleic acid content, as well as their cargo of functional molecules, such as enzymes, growth factors, and microRNAs. The cargo of exosomes is thought to reflect the functional state of the cell that releases them, and exosomes can therefore be used as a source of biomarkers for disease diagnosis or as a tool for therapeutic intervention. Furthermore, exosomes from different cell types have been shown to have different functions, such as promoting or inhibiting immune responses or modulating tumor growth and metastasis. Therefore, it is important to carefully characterize the exosomes of interest in order to fully understand their properties and potential applications.
We have partnered with Neobiosis to use their purified amniotic fluid (PAF) exosome product. Amniotic fluid flowable tissue differs in source material, quality of manufacturing, sterilization technique, size, concentration, protein and RNA concentration and potential risk of fungal and bacterial contamination. Our Purified Amniotic Fluids are refined, which produces a crystal-clear product, never pink (red blood cell contamination) and never cloudy (suggestive of contamination with microvesicles and apoptotic bodies, which may inhibit the regenerative process or induce inflammation, compromising research and clinical trial outcomes). Neobiosis PAF are minimally manipulated, twice sterile filtered, and never UV irradiated.
Exosomes are being used as a therapeutic tool for a variety of conditions. They have been investigated for their ability to deliver drugs or therapeutic molecules, as well as for their ability to promote tissue regeneration and modulate the immune response. Some of the conditions that exosomes are being studied to treat include:
- Cancer: Exosomes are being investigated as a way to deliver drugs or genetic material to cancer cells or to stimulate the immune system to attack cancer cells.
- Neurological disorders: Exosomes may be able to cross the blood-brain barrier and deliver therapeutic molecules to the brain, making them a potential treatment for neurodegenerative disorders, such as Alzheimer’s disease and Parkinson’s disease.
- Cardiovascular disease: Exosomes may be able to promote the regeneration of damaged tissue and improve blood vessel function, making them a potential treatment for cardiovascular diseases, such as heart attack and stroke.
- Inflammatory and autoimmune disorders: Exosomes have been shown to have anti-inflammatory properties and may be able to modulate the immune response, making them a potential treatment for inflammatory and autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.
platelet-rich plasma (PRP)
Platelet-rich plasma (PRP) is a preparation of a patient’s own blood that is enriched with a high concentration of platelets. Platelets are blood cells that play a key role in clotting and wound healing. PRP is typically prepared by collecting a small amount of the patient’s blood, and then processing it in a centrifuge to separate out the platelets and concentrate them into a small volume of plasma. The resulting PRP preparation is then injected into the patient’s body at the site of injury or tissue damage to promote healing and tissue regeneration.
Platelet-rich plasma has anti-inflammatory effects, which contribute to its therapeutic effects in certain medical conditions. PRP contains various growth factors and other bioactive molecules, such as cytokines, chemokines, and microRNAs, which modulate the immune response and reduce inflammation. The growth factors in PRP can stimulate tissue repair and regeneration, which can help to reduce the extent of tissue damage and the resulting inflammation. PRP has been shown to promote the proliferation and differentiation of various cell types, including mesenchymal stem cells, which can differentiate into different cell types, such as bone, cartilage, and muscle. These cells have been shown to have immunomodulatory effects, which can help to reduce inflammation and promote tissue healing.
Inflammation is a natural process that occurs in the body in response to injury or infection. It is a complex biological response that involves the activation of various cells, cytokines, and other molecules to remove the source of the injury or infection and initiate tissue repair.
While inflammation is an important protective response, chronic or excessive inflammation can have negative effects on the body. Prolonged or unresolved inflammation can damage healthy tissues and contribute to the development of many diseases, such as rheumatoid arthritis, atherosclerosis, type 2 diabetes, and certain cancers.
Chronic inflammation can also affect the immune system and increase the risk of autoimmune diseases, in which the immune system attacks healthy tissues in the body. In addition, chronic inflammation has been linked to aging and age-related diseases, such as Alzheimer’s disease, osteoporosis, and cardiovascular disease. Therefore, reducing chronic inflammation in the body is an important goal for promoting health and preventing disease.
PRP has been shown to inhibit the expression of pro-inflammatory cytokines, such as interleukin-1 beta and tumor necrosis factor alpha, which are involved in the inflammatory response. PRP has also been shown to increase the expression of anti-inflammatory cytokines, such as interleukin-10, which can help to counteract the effects of pro-inflammatory cytokines.
PRP has been used in a variety of medical fields, including orthopedics, sports medicine, and dermatology post-surgical, cosmetics, veterinary medicine, and erectile dysfunction. In orthopedics and sports medicine, PRP has been used to treat soft tissue injuries, such as tendonitis and ligament sprains, as well as osteoarthritis. In dermatology, PRP has been used for facial rejuvenation and to promote hair growth in patients with hair loss.
Platelet-Rich Plasma with Exosomes is a proprietary product that Eterna is bringing to market. While exosomes are heavily regulated by the FDA, we have devised a system using ultracentrifugation to extract exosomes from the patient’s blood. The exosomes are then combined with the PRP for re-injection. This formula has allowed us to offer a product that features a tenfold increase in anti-inflammatory markers, which can be used for a much wider range of treatments while adhering to FDA regulations.
gene editing
Gene editing is a process of making precise, intentional changes to the DNA sequence of an organism’s genome. It involves the use of engineered nucleases, such as CRISPR-Cas9, to cut DNA at specific locations and then introduce new genetic material to the cut site, either by repairing the cut using the cell’s natural repair mechanisms or by inserting new genetic material.
This technology can be used to add, delete, or replace specific genes or gene sequences in an organism’s genome. Gene editing has the potential to provide new treatments for genetic diseases by correcting or modifying the genetic mutations that cause them. It can also be used to create new crop varieties, improve livestock breeds, and develop new industrial and pharmaceutical products.
The most widely used gene editing technology is CRISPR-Cas9, which involves the use of a guide RNA (gRNA) and a nuclease enzyme, Cas9. The gRNA is designed to recognize and bind to a specific DNA sequence, guiding the Cas9 enzyme to that location in the genome. Once the Cas9 enzyme is bound to the DNA, it cuts the DNA strands at the targeted location. This creates a doublestrand break, which activates the cell’s natural DNA repair mechanisms.
There are two main types of DNA repair mechanisms that can be harnessed to introduce specific changes to the genome: non-homologous end joining (NHEJ) and homology-directed repair (HDR). NHEJ is a quick and simple mechanism that repairs the double-strand break by directly joining the two cut ends of the DNA, often leading to the insertion or deletion of genetic material at the cut site. HDR, on the other hand, can be used to introduce more precise changes by using a DNA template to repair the cut site, leading to the introduction of specific genetic changes.
Eterna has partnered with Minicircle to bring the world’s first reversible gene editing technology to the market. We are using highly expressive DNA plasmids to add genes to the human body without altering your pre-existing genome. Our reversible plasmid platform is completely non-inflammatory (unlike AAV) and non-heritable. It is designed as a universal gene therapy protocol.
Plasmids are small circular loops of DNA that are completely non-inflammatory, easy to manufacture and distribute, do not integrate into or edit your original chromosome, are not heritable, and can be designed to include responsive switches allowing the gene to be turned on or off via the consumption of an activator pill – making treatment reversible.
We have designed these plasmids as a friendly and safe universal platform for reversible gene therapy. Plasmid therapy promises unlimited health, independence from disease, and to reimagine the future of our identity.
All Gene Therapies are equipped with a genetic kill-switch encoded into the DNA where the plasmids are destroyed in the presence of the common antibiotic tetracycline.
Minicircle currently has trials underway to cure HIV, ALS, Muscular Dystrophy, Herpes, Low Testosterone, Dyskeratosis Congenita, Crohn’s Disease and General Obesity with several other Tissue Regeneration, Antibody Delivery and DNA Repair Programs underway.